Get started

Pharmaceuticals

It's hard to overstate how important the NVAX Phase 3 result isNovavax's Nanoflu isn't your typical new drug-- it's a whole new pharmaceutical technology. So it's hard to overstate how important today's positive Phase 3 clinical trial result is. Positive Phase 3 trial data this morning suggest that Novavax's Virus-Like Particle (VLP)-based flu vaccines will be much more effective than existing egg-based vaccines. When you make a vaccine in an egg, it can mutate in the egg and no longer match the flu strains it's supposed to prevent. The VLP vaccines, by contrast, are genetically identical to the targeted flu strains. This increases the vaccines' effectiveness against the targeted strains. Nanoflu also includes something called "adjuvant Matrix-M," which increases the number of antibodies produced in response to the vaccine by something on the order of 50%. Stronger immune response means greater effectiveness, though it also modestly increased the incidence of adverse events in Novavax's trial. One particular important result from the Phase 3 trial was that Nanoflu was more effective than its competitors against A/H3N2, the most lethal family of flu viruses and the one against which vaccines have traditionally been least effective. I have some friends doing work in this field, and they've told me that there are three really exciting things about these VLP vaccines: 1) they aren't infectious, which makes them safer than using an attenuated virus, 2) they protect against not only the strain of virus they target, but also some mutant forms of it, and 3) they take 12 weeks to produce rather than the traditional 9 months. This last point is the real game-changer. Imagine being able to get vaccines to market in a third of the traditional time. Novavax is also working on a VLP-based Covid-19 vaccine. We can probably expect the FDA to rush approval of both Nanoflu and the CoV-19 vaccine.
NASDAQ:NVAXLong
by ChristopherCarrollSmith
5
BMY is worth buyingBristol-Myers Squibb says it has seen no major business disruptions and expects no decrease in global demand for its drugs this year. That means the 3.5% dividend yield should stay stable, and BMY is a great value at 1.3 PEG. BMY also just got FDA approval for a multiple sclerosis drug, which could turn out to be a pretty big deal. Most of the market has been trading based on macroeconomics, but as individual companies like BMY issue quantitative guidance, I think we're going to see more trading on company specifics. I bought a small position here and will add the dip if BMY heads south with the rest of the market next week.
NYSE:BMYLong
by ChristopherCarrollSmith
8
Healthcare probably going to take a hit this weekCongress's coronavirus stimulus deal reached Friday night included a provision requiring health insurers to bear the full cost of coronavirus test kits and to waive copays. The federal government will pay the cost for the uninsured. This will probably hurt health insurers Monday, though it might be good for service providers. Here's another piece of bad news: xenophobia related to the virus has angered the Chinese government, and China’s official newspaper Xinhua published a threat to cut off supply chains for the US pharmaceutical industry. If China followed through on this threat, there could be big US drug shortages, which would be bad for pharmaceutical and healthcare companies. The whole economy will be down this week due to expanding quarantines, new travel bans, and the failure of Trump's payroll tax cut proposal, but the healthcare sector may take extra damage Monday as it bears the brunt of the cost of coronavirus testing.
AMEX:XLVShort
by ChristopherCarrollSmith
4
BEAT- BEAST is about to be unleashed...Positional/swing tradeBEAT is your prototypical aggressive growth stock- Strong future growth potential with good earning and revenue track record ... If you can overlook its debt level. This beast was tamed for a while after its share price skyrocketed from $25 to almost $80 , but it is ready to unleash its fury again. But first, I think the pullback is in the store facing key resistance lvl in confluence with ichi and BB on the weekly timeframe. In addition, short % of float is around 10%. However, it is a bullish sign when price hovers below the key resistance lvl rather than experiencing outright price rejection. My buy zone is between $45 to $55 for the positional trade. The long term trendline and S/R flip below this price range will act as a strong support. Click the like button and follow me if you like my analysis :D
NASDAQ:BEAT
by Libratus
Biogen: Sell opportunity.BIIB closed the week around +25% as news regarding a crucial patent ruling came out in the company's favor. With the company's earnings also higher than the forecast, investors seem upbeat with the stock's dynamics. Even though the 1D chart turned overbought (RSI = 75.219, MACD = 6.690), on the weekly chart there is still a clear Resistance Zone at 370.00 - 389.00 which has been holding since 2016. The fact that the 1W candle pulled back making a big wick right after it entered the Resistance Zone, indicates that traders looked to book profits first. We see this as a strong sell opportunity towards at least the 267.00 Gap or even the 246.70 Symmetrical Support. ** If you like our free content follow our profile (www.tradingview.com) to get more daily ideas. ** Comments and likes are greatly appreciated.
NASDAQ:BIIBShort
by InvestingScope
ABBV should soon find support for a bounceAbbvie has been falling hard on news that it will sell off some drug patents in order to win approval for its merger with Allergan. It is entering a support zone between about $77 and $81, however, and it may start to climb from here as investors start to get excited about the merger. Also look for Coronavirus news to move the stock; word on the street is that one of Abbvie's drugs is being used off-label to treat Coronavirus patients. With a 5.67% dividend yield and a forward P/E under 10, ABBV looks attractively valued. True, the patent sales will probably negatively affect that forward P/E, and the merger might ultimately result in a lower dividend yield. But Abbvie will also pocket a bunch of cash from those drug sales that can be used to grow its pipeline, and Allergan's forward P/E is also low, with plenty of potential upside.
NYSE:ABBVLong
by ChristopherCarrollSmith
2
Buckle up! Falling Wedge pattern on Daily Ready to Rocket!Perfect close yesterday to bounce off support into a major move up! This is what we have been waiting for! Notes: -Stochastic: is sitting in a good spot: Neutral ( Not oversold or Over bought) -On Balance Volume: Still trending up on the daily very strong sign, especially with the price decline in the short term, The OBV hints at strong momentum still. -Falling Wedge: Setup is perfect. Its very clean and we are in a good spot! -20 MA: to 20 moving average is a great support and sets up for a larger stronger bounce after a deep pullback like this. -SSR in place today so Bulls can really have an advantage here! -Pre Market: Off to a hot start! Good Luck and Buy Buy Buy!!!!
ALong
by JaxelCap